Promising Developments That May Improve Lupus Nephritis Management
Recent approval of new drugs for lupus nephritis and promising therapies on the horizon bode well for the care of patients with the kidney disorder.
Systemic Lupus Erythematosus
New Drug Product: Saphnelo
This slideshow shows drug information for Saphnelo. Click here for the complete Saphnelo monograph.
MPR Weekly Dose Podcast Episode 88
The FDA authorizes a postexposure prophylaxis for COVID-19; A new treatment is okay’d for lupus; A higher dose naloxone nasal spray became available; The risk evaluation and mitigation program for Clozapine has had important changes, and finally, Istodax has had an indication withdrawn.
Saphnelo Approved for Systemic Lupus Erythematosus
The Food and Drug Administration (FDA) has approved Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy. Type I interferons (IFNs) play a role in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab-fnia, a human immunoglobulin G1 kappa monoclonal antibody, binds to subunit 1 of…
Clinical Challenge: Diffuse Rash Affecting Fingertips
A 28-year-old woman presents with fever and a diffuse rash. One year ago, the woman was at the hospital dermatology department with fever, malar rash, arthralgia, and hematuria. Her medical history documented recurrent painful oral ulcers and photosensitivity. The diagnostic workup at that time revealed systemic lupus erythematosus (SLE) with cutaneous and renal involvement. The…
Belimumab Shows Longer-Term Safety, Efficacy in Lupus Nephritis
The proportion of patients with lupus nephritis achieving renal response with belimumab increased during a 6-month extension study.
Hydroxychloroquine Level Tied to Thrombosis Risk in Lupus
Rate of thrombotic events lower for patients with mean HCQ blood levels >1,068 versus <648 ng/mL
New Study Supports Voclosporin Use in Lupus Nephritis Cases
Pooled analyses from 2 clinical trials show that voclosporin, a novel calcineurin inhibitor, is safe and effective in managing lupus nephritis.
Newly Diagnosed Lupus Erythematosus Could Potentially Be Drug Induced
A new case of cutaneous lupus erythematosus or systemic lupus erythematosus could potentially be drug induced.
MPR Weekly Dose Podcast Episode 44
This week: The government makes a $1.95 billion deal for a COVID-19 vaccine; Promising data from the Oxford vaccine trial; The CDC retakes control of COVID-19 data; Novel calcineurin inhibitor for lupus nephritis gets priority review; And there’s new treatment for narcolepsy.
